

South Carolina Department of Health and Human Services  
(SCDHHS) Pharmacy and Therapeutics Committee

<https://scdhhs-events.webex.com/weblink/register/r873c81c444b045ef8bb48c8a44a2d816>

Webinar password: dhhs

Wednesday, November 6, 2024, 4:00p

A G E N D A

I. Welcome..... Dr. Edward Behling, MD

*Freedom of Information Act/Americans With Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.*

II. Roll Call .....Cheryl Anderson, RPh

III. Approval of Minutes from August 6, 2024 ..... P&T Committee

IV. State Updates ..... Dr. Kevin Wessinger, MD and Cheryl Anderson, RPh

V. Public Comment - Drug Classes

a. Presenters must pre-register with SCDHHS no less than seven days in advance of the meeting. Testimony will be limited to three minutes, and there will be only one speaker per pharmaceutical agent under consideration. P&T Committee members may use an additional two minutes to ask the speaker questions, if warranted. Please e-mail the speaker's name, the product they will discuss, and the CV of the speaker. Additionally, a completed speaker disclosure statement must be faxed to our P&T Pharmacist at 888-656-1239. The form can be found at: <http://southcarolina.fhsc.com/providers/ptcommittee.asp>. SCDHHS will need all of this information no later than the close of business October 31, 2024. Emails may be sent to [scsinglepdl@primetherapeutics.com](mailto:scsinglepdl@primetherapeutics.com) or via fax to (888) 656- 1239.

b. Criteria for Re-Reviews: Previously reviewed therapeutic classes from PDL phases subject to re-review may be opened for re-review if one or more of the following has occurred: a) a new drug in the therapeutic class, b) a new indication for an existing drug in the therapeutic class, c) a new study recognized and generally accepted by

the medical community or three peer-reviewed studies for a drug in the therapeutic class.

VI. Drug Classes for P&T Committee Review ..... P&T Committee

**Classes for Review:**

- **Injectable Immunomodulators**
  - **Asthma**
  - **Prurigo Nodularis**
  - **Chronic Rhinosinusitis with Nasal Polyposis**
  - **Chronic Spontaneous Urticaria**
  - **Eosinophilic Esophagitis**
  - **IGE Mediated Food Allergy**
  - **Eosinophilic Granulomatosis with Polyangitis**
  - **Hypereosinophilic Syndrome**
- **Sickle Cell (Oral)**
- **Ophthalmic Antibiotics**

**Classes for Re-review:**

- **Ophthalmic Quinolones & Macrolides**
- **Attention Deficit Hyperactivity Disorder Agents**
- **COPD Agents, Inhaled and Oral**
- **Gastrointestinal Antimicrobials**
- **Electrolyte Modifiers**

VII. Old Business ..... P&T Committee

VIII. New Business ..... P&T Committee

Next P&T Meeting – February 5, 2025

IX. Adjournment